For full-year 2025, NeoGenomics reported total revenue of $727 million , up 10% versus 2024. Clinical revenue increased 15% (or 13% excluding the PathLine acquisition), while non-clinical revenue declined 24% for the year. Adjusted gross profit increased $23 million , or 8% , to $335 million , and adjusted EBITDA rose 9% to $43.4 million . Cash flow from operations was positive $5 million in 2025, and the company reported that free cash flow improved by over 35% compared with 2024.Chief Financial Officer Je ...

NeoGenomics (NasdaqCM:NEO) Q4 2025 Earnings call February 17, 2026 08:30 AM ET Speaker11Good morning, and welcome to the NeoGenomics fourth quarter and full year 2025 financial results call. Please be advised that today's conference is being recorded. I will now turn the call over to Kendra Webster with NeoGenomics. The floor is yours.Speaker8Thank you, Kelly, and good morning, everyone. Welcome to the NeoGenomics fourth quarter and full year 2025 financial results call. With me today to discuss the results ...

Q4 and FY 2025 Financial Results February 17, 2026 Nasdaq: NEO Safe Harbor Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company"). Statements contained herein are made as of the date of this presentation unless stated otherwise. This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "would," "may," "will," "believe, ...

Key Takeaways NeoGenomics launches PanTracer Pro to streamline testing for advanced solid tumors.NEO says the assay pairs DNA/RNA sequencing of 500 genes with IHC to guide therapy and trials.NeoGenomics reported Q4 sales near $190M, up 11%, and expects double-digit growth in 2026.NeoGenomics, Inc. (NEO) recently announced the availability of its new pan-solid tumor assay, PanTracer Pro, designed to help clinicians navigate increasingly complex molecular testing workflows to make informed decisions for patie ...

(unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.## ContactsInvestor Contact Kendra Webster [InvestorRelations@neogenomics.com]Media Contact Andrea Sampson [asampson@sampsonprgroup.com]Industry:- [Genetics]- [Hospitals]- [Medical Devices]- [ ...